Governance
Code of Ethics and Conduct
Version 1.0 · Approved by Dean Bitan · Review date: October 1, 2026
1. Purpose and Scope
Imagene AI Ltd. (the “Company”) is committed to conducting its business with integrity, respect and sound judgment. This Code sets out the principles that guide our work, business relationships and responsible innovation in AI and precision oncology.
The Code applies to all Company directors, officers, managers and employees. Contractors, consultants and other representatives acting on the Company’s behalf are expected to follow the standards relevant to their activities, as reflected in their contractual obligations.
The Code provides practical guidance but cannot address every situation. Everyone covered by it is expected to exercise sound judgment, seek guidance when unsure and raise concerns about suspected misconduct. Managers are expected to lead by example, support open communication without fear of retaliation and ensure that concerns brought to their attention are appropriately addressed or referred through the channels set out in Section 8.
This Code should be read together with applicable law, contractual obligations and relevant Company policies. It does not replace or override those requirements. If these requirements appear to conflict, or their application is unclear, seek guidance through the channels set out in Section 8. Nothing in this Code limits any reporting, disclosure or other activity permitted or protected by applicable law.
2. Our Mission
Imagene AI is a precision oncology company developing AI-powered pathology and multimodal biomarker solutions for biopharmaceutical research, clinical development and diagnostics. Our mission is to advance precision oncology by helping researchers and healthcare professionals gain meaningful insights from pathology images and molecular and clinical data, supporting the development of treatments and more informed patient care.
We combine proprietary AI models, computational pathology and real-world patient data to support biomarker discovery, patient stratification, treatment-response prediction and companion diagnostic development. Through collaboration with biopharmaceutical companies, diagnostic partners and medical institutions, we work to translate scientific innovation into validated solutions with meaningful benefits for patients, guided by scientific rigour, responsible development and respect for patient safety and privacy.
3. Ethical Principles
Our work and business relationships are guided by the following principles:
- Patient-First Mindset: We put patients at the centre of our mission and consider how our work may affect their lives and well-being. We pursue meaningful, evidence-based impact while respecting patient safety, privacy and the role of qualified healthcare professionals.
- Integrity: We communicate truthfully, accurately and clearly, so that others understand both the facts and their material limitations. We rely on trustworthy sources, avoid exaggerating achievements or concealing mistakes, and seek guidance when faced with ethical uncertainty.
- Ownership and Accountability: We take responsibility for our commitments, actions and results. We lead by example, follow through on our responsibilities and involve others when their expertise or support is needed. We acknowledge mistakes promptly, help address them and raise concerns rather than allowing them to go unresolved.
- Collaboration and Respect: We work as one team, treat others with care and respect, and share knowledge and ideas across functions. We welcome constructive feedback, different perspectives and open discussion, including questions or concerns that challenge existing approaches.
- Innovation, Excellence and Continuous Learning: We welcome challenges and pursue responsible innovation. We strive for high-quality work, develop our skills and learn from evidence, feedback and experience to improve our products, processes and decisions.
- Efficiency and Meaningful Outcomes: We focus on work that matters, set clear objectives and prioritise activities that advance our mission. We use time and resources responsibly, communicate with purpose and assess progress using relevant, reliable measures, without overstating our impact.
- Drive and Responsible Urgency: We act proactively and with a strong commitment to delivery. We address obstacles, make timely decisions and pursue ambitious goals, without compromising integrity, quality, patient safety, privacy or applicable requirements. Urgency must never discourage appropriate review, questions or the reporting of concerns.
4. People and Business Relationships
4.1 Employees and Job Applicants
Imagene is committed to a respectful, inclusive and safe workplace. Employment decisions must be based on relevant qualifications, performance and business needs. Discrimination based on race, religion, gender, age, disability or any other legally protected characteristic is prohibited, as are harassment, bullying and retaliation.
At Imagene we support gender equality, including equal access to recruitment, development and leadership opportunities, and equal pay for work of equal value, consistent with applicable law. As we grow, we seek to attract qualified candidates from diverse and underrepresented backgrounds through fair and inclusive recruitment practices.
Employees must treat others respectfully, follow workplace and safety requirements, and raise concerns about inappropriate or unsafe conduct through the channels set out in Section 8, without first having to approach their manager. Imagene respects employee privacy in accordance with applicable law.
We support professional development through constructive feedback and learning opportunities appropriate to employees’ roles, development needs and available resources. Employees are encouraged to share knowledge, give and receive constructive feedback, and discuss training needs and career interests with their managers.
4.2 Customers and Users
We communicate honestly and clearly about our products and services. Claims about capabilities, performance, validation and intended uses must be supported by appropriate evidence and consistent with applicable requirements. Material limitations must be clearly communicated, and research findings must not be presented as establishing suitability for clinical use without appropriate validation. Customer and user information must be handled only for authorised purposes and in accordance with applicable requirements. Product complaints, safety concerns and reports of potential harm must be promptly referred to the responsible product lead for appropriate handling.
4.3 Suppliers and Business Partners
We select and work with suppliers and business partners based on legitimate business considerations, such as quality, expertise, reliability and cost. We consider relevant risks, including information security and ethical conduct, in a manner proportionate to the nature of the relationship.
We expect suppliers and partners to comply with applicable law and respect human rights, including prohibitions on forced labour, child labour and human trafficking.
Employees must disclose conflicts of interest, avoid improper benefits and report material concerns about a supplier’s or partner’s conduct through the reporting channels set out in Section 8. The Company will consider an appropriate response based on the nature and seriousness of the concern.
4.4 Investors and Public Authorities
Information provided on Imagene’s behalf to investors, shareholders or public authorities must be accurate, not misleading and appropriately authorised. Material statements must be supported and include relevant qualifications or limitations.
Official requests and regulatory questions must be referred internally to the function responsible for the matter. Only authorised persons may respond on the Company’s behalf. This does not restrict anyone from making a report or disclosure permitted or protected by applicable law.
5. Responsible Development and Use of AI
Imagene is committed to developing and using AI responsibly, considering its intended uses and reasonably foreseeable effects on patients, users and others. Development and use must be appropriate to the relevant research or clinical purpose and comply with applicable requirements.
Assessment, testing and oversight should be proportionate to the system’s development stage, intended use and associated risks. Relevant measures include:
- Reviewing data quality, suitability and permitted use.
- Assessing performance, potential bias and material limitations.
- Testing and validation appropriate to the intended use before release, and reassessment following material changes to determine whether further testing or validation is needed, considering their potential impact on performance, safety and intended use.
- Providing human review or oversight appropriate to the system’s intended use and associated risks, while respecting the role of qualified healthcare professionals in clinical decisions.
- Communicating limitations and conditions of use.
- Reviewing credible reports of material errors, misuse or harmful outcomes.
Research, testing and validation results must be recorded and presented accurately, including material findings that do not support the expected outcome. Key development and validation decisions should be documented to support traceability and review. Findings must not imply suitability for clinical or other uses that have not been appropriately validated.
Employees must promptly raise material concerns about data quality, model performance, unsupported claims or use outside the intended scope with the responsible product or technical lead.
This Code does not replace technical validation, security review or any legal, regulatory or contractual assessment required for a particular use.
6. Business Integrity
6.1 Anti-Bribery
Imagene does not tolerate bribery or corruption. We must not offer or accept anything of value to improperly influence a decision or obtain an improper business advantage, whether directly or through a third party. Significant or unusual benefits, and benefits involving public officials, require prior approval. Approval does not make an otherwise improper benefit permissible. Donations and sponsorships must be authorised, accurately recorded and must not be used to obtain an improper advantage.
Interactions with healthcare professionals and healthcare institutions must be professional and comply with applicable requirements. Gifts, hospitality, fees and other benefits must not improperly influence clinical judgment, purchasing decisions, referrals or research outcomes. Payments must be for legitimate services, reasonable in relation to the services provided and appropriately documented.
6.2 Conflicts of Interest
An actual, potential or apparent conflict may arise where a personal or financial interest affects, or could reasonably appear to affect, a person’s responsibilities to Imagene.
Examples include:
- Having a financial interest in a supplier, customer or competitor that could influence, or reasonably appear to influence, business judgment.
- Engaging in business activities that conflict with Company interests or interfere with the person’s responsibilities to the Company.
- Using Company information, assets or business opportunities for personal benefit.
Actual, potential or apparent conflicts of interest must be disclosed promptly to the person’s manager, wherever possible before taking part in the relevant decision or activity. If the manager is involved, another reporting channel set out in Section 8 must be used. The Company will determine whether any steps are needed to manage the conflict, such as not participating in a decision. Having or disclosing a conflict does not, by itself, mean that misconduct has occurred.
6.3 Records and Company Assets
Fraud, theft, forgery and deliberate misrepresentation are prohibited.
Business records, including invoices, expenses, financial information and technical or operational reports, must accurately reflect the underlying activity. Records must not be falsified, improperly altered or deliberately concealed. Company funds, equipment, systems, credentials, intellectual property and other resources must be protected and used for authorised purposes.
Records must be retained or disposed of in accordance with applicable requirements and Company instructions. Records relevant to an ongoing or reasonably anticipated investigation or legal proceeding must not be destroyed.
6.4 Fair Competition
Imagene competes independently and fairly. Employees must not enter into improper agreements or coordinate with competitors on prices, bids, customers, markets or other competitive matters. Competitively sensitive information must not be shared with competitors unless there is a legitimate and lawful basis for doing so. If in doubt, seek guidance before sharing.
7. Information, Privacy and Security
Employees and other authorised representatives must protect Company information and information entrusted to Imagene, including personal and health data, confidential business information and intellectual property.
In particular:
- Access and use information only for authorised purposes and to the extent needed for the relevant task.
- Use approved systems, tools and access arrangements, and protect devices, passwords and other credentials.
- Collect and handle personal information only as permitted by applicable law, contractual obligations and Company instructions.
- Apply appropriate safeguards to sensitive information, including health and genomic data. Pseudonymised data must not be treated as anonymous, and individuals must not be re-identified without appropriate authorisation and a lawful basis.
- Share information externally only when authorised and with appropriate safeguards, including for transfers across borders.
- Follow requirements for retaining, returning and securely disposing of information, and promptly refer requests concerning individuals’ personal data rights to the person responsible for privacy matters at the Company.
Confidential information must not be used or disclosed without authorisation. Confidentiality obligations continue after employment or engagement ends, subject to disclosures permitted or protected by applicable law. The confidential information and intellectual property rights of others must also be respected.
Suspected loss, unauthorised access, disclosure or misuse must be reported promptly to the person responsible for information security or the relevant technical lead. Reporting must not be delayed while attempting to confirm or resolve the issue independently.
Imagene maintains an information security management system certified to ISO/IEC 27001:2022 and ISO 27799, supporting the protection, confidentiality, integrity and availability of information throughout its lifecycle. Everyone handling Company information or information entrusted to Imagene must follow the security requirements and instructions relevant to their role.
8. Questions, Concerns and Non-Retaliation
Employees are encouraged to seek guidance when unsure and must promptly raise concerns about suspected violations of this Code, applicable law or Company requirements. Proof of a violation is not required before raising a concern.
Questions and concerns may be raised with:
- The employee’s manager.
- Mirel Bitan – HR and Operations Manager
- Dean Bitan – CEO
Employees may use any of these channels without first approaching their manager. If a concern involves a particular contact, or the employee is uncomfortable approaching them, another channel should be used.
Imagene will assess concerns promptly, fairly and with appropriate discretion. Reviews should be conducted by people free from conflicts of interest, with external assistance where appropriate. Employees are expected to cooperate honestly with reviews. Where appropriate and permitted, the Company will provide the reporting person with updates, while respecting confidentiality and the rights of those involved.
Information will be shared only as reasonably necessary to assess or address the concern or meet applicable legal requirements. Absolute confidentiality cannot be guaranteed.
Retaliation against anyone who raises a concern in good faith or assists with a review is prohibited, even if the concern is not substantiated. Suspected retaliation must also be reported. Knowingly providing false information or deliberately making a false report may result in disciplinary action; an honest mistake does not constitute a false report.
Nothing in this Code restricts anyone from making a report or disclosure, cooperating with a public authority or exercising any other right permitted or protected by applicable law. No prior Company approval or notification is required for such protected activities.
9. Communication and Breaches
Imagene will make this Code accessible to those covered by it and provide guidance and training appropriate to their roles and relevant risks. Employees must complete required training and acknowledge receipt and understanding of the Code when requested.
Managers must lead by example, help employees understand the standards relevant to their work and support the reporting and appropriate handling of concerns.
Suspected breaches will be assessed fairly and consistently. Confirmed breaches may result in corrective or disciplinary action, up to and including termination of employment or engagement, subject to applicable law and contractual requirements. Where appropriate, the Company will address underlying causes through improvements to policies, training or controls.
10. Review and Document Control
Mirel Bitan – HR and Operations Manager is responsible for maintaining this Code and coordinating its review at least annually, or earlier following material changes in the Company’s activities, risks or applicable requirements.
Material updates must be approved by Executive Management and communicated to those affected. The document owner will maintain the current approved version and a record of material changes.